



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

Krtap4-9 siRNA (m): sc-151404

BACKGROUND

Chromosome 17 makes up over 2.5% of the human genome with about 81 million bases encoding over 1,200 genes. Two key tumor suppressor genes are associated with chromosome 17, namely, p53 and BRCA1. Tumor suppressor p53 is necessary for maintenance of cellular genetic integrity by moderating cell fate through DNA repair versus cell death. Malfunction or loss of p53 expression is associated with malignant cell growth and Li-Fraumeni syndrome. Like p53, BRCA1 is directly involved in DNA repair, though specifically it is recognized as a genetic determinant of early onset breast cancer and predisposition to cancers of the ovary, colon, prostate gland and fallopian tubes. Chromosome 17 is also linked to neurofibromatosis, a condition characterized by neural and epidermal lesions, and dysregulated Schwann cell growth. Alexander disease, Birt-Hogg-Dube syndrome and Canavan disease are also associated with chromosome 17.

REFERENCES

1. Welsch, M.J., Kronic, A. and Medenica, M.M. 2005. Birt-Hogg-Dube syndrome. *Int. J. Dermatol.* 44: 668-673.
2. Nusbaum, R., Vogel, K.J. and Ready, K. 2006-2007. Susceptibility to breast cancer: hereditary syndromes and low penetrance genes. *Breast Dis.* 27: 21-50.
3. Al-Dirbashi, O.Y., Rashed, M.S., Al-Qahtani, K., Al-Mokhadab, M.A., Kurdi, W. and Al-Sayed, M.A. 2007. Quantification of N-acetylaspartic acid in urine by LC-MS/MS for the diagnosis of Canavan disease. *J. Inherit. Metab. Dis.* 30: 612.
4. Dann, R.B., Kelley, J.L. and Zorn, K.K. 2007. Strategies for ovarian cancer prevention. *Obstet. Gynecol. Clin. North Am.* 34: 667-686.
5. Farrell, C.J. and Plotkin, S.R. 2007. Genetic causes of brain tumors: neurofibromatosis, tuberous sclerosis, von Hippel-Lindau, and other syndromes. *Neurol. Clin.* 25: 925-946.
6. Suela, J., Largo, C., Ferreira, B., Alvarez, S., Robledo, M., González-Neira, A., Calasanz, M.J. and Cigudosa, J.C. 2007. Neurofibromatosis 1, and not TP53, seems to be the main target of chromosome 17 deletions in *de novo* acute myeloid leukemia. *J. Clin. Oncol.* 25: 1151-1152.
7. Tai, Y.C., Domchek, S., Parmigiani, G. and Chen, S. 2007. Breast cancer risk among male BRCA1 and BRCA2 mutation carriers. *J. Natl. Cancer Inst.* 99: 1811-1814.
8. Yan, J., Jiang, J., Lim, C.A., Wu, Q., Ng, H.H. and Chin, K.C. 2007. Blimp-1 regulates cell growth through repression of p53 transcription. *Proc. Natl. Acad. Sci. USA* 104: 1841-1846.
9. Murakami, N., Tsuchiya, T., Kanazawa, N., Tsujino, S. and Nagai, T. 2008. Novel deletion mutation in GFAP gene in an infantile form of Alexander disease. *Pediatr. Neurol.* 38: 50-52.

CHROMOSOMAL LOCATION

Genetic locus: Krtap4-9 (mouse) mapping to 11 D.

RESEARCH USE

For research use only, not for use in diagnostic procedures.

PRODUCT

Krtap4-9 siRNA (m) is a target-specific 19-25 nt siRNA designed to knock down gene expression. Each vial contains 3.3 nmol of lyophilized siRNA, sufficient for a 10 μ M solution once resuspended using protocol below. Suitable for 50-100 transfections. Also see Krtap4-9 shRNA Plasmid (m): sc-151404-SH and Krtap4-9 shRNA (m) Lentiviral Particles: sc-151404-V as alternate gene silencing products.

STORAGE AND RESUSPENSION

Store lyophilized siRNA duplex at -20° C with desiccant. Stable for at least one year from the date of shipment. Once resuspended, store at -20° C, avoid contact with RNAses and repeated freeze thaw cycles.

Resuspend lyophilized siRNA duplex in 330 μ l of the RNase-free water provided. Resuspension of the siRNA duplex in 330 μ l of RNase-free water makes a 10 μ M solution in a 10 μ M Tris-HCl, pH 8.0, 20 mM NaCl, 1 mM EDTA buffered solution.

APPLICATIONS

Krtap4-9 siRNA (m) is recommended for the inhibition of Krtap4-9 expression in mouse cells.

SUPPORT REAGENTS

For optimal siRNA transfection efficiency, Santa Cruz Biotechnology's siRNA Transfection Reagent: sc-29528 (0.3 ml), siRNA Transfection Medium: sc-36868 (20 ml) and siRNA Dilution Buffer: sc-29527 (1.5 ml) are recommended. Control siRNAs or Fluorescein Conjugated Control siRNAs are available as 10 μ M in 66 μ l. Each contain a scrambled sequence that will not lead to the specific degradation of any known cellular mRNA. Fluorescein Conjugated Control siRNAs include: sc-36869, sc-44239, sc-44240 and sc-44241. Control siRNAs include: sc-37007, sc-44230, sc-44231, sc-44232, sc-44233, sc-44234, sc-44235, sc-44236, sc-44237 and sc-44238.

RT-PCR REAGENTS

Semi-quantitative RT-PCR may be performed to monitor Krtap4-9 gene expression knockdown using RT-PCR Primer: Krtap4-9 (m)-PR: sc-151404-PR (20 μ l). Annealing temperature for the primers should be 55-60° C and the extension temperature should be 68-72° C.

PROTOCOLS

See our web site at www.scbt.com for detailed protocols and support products.